LUNG CANCER SCREENING & SMOKING CESSATION

Slides:



Advertisements
Similar presentations
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.
Advertisements

Chairman Department Radiation Oncology Sophia Gordon Cancer Center
Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.
J Thorac Dis 2013;5(S5) Estimated 10 year survival 88%, regardless of treatment Survival rate 92% if surgical resection in 1 month.
Goldstraw et al. J Thorac Oncol 2007 Why should we want to screen? Survival (years)
Canadian Cancer Risk Management Model: A new health policy tool useful in policy decisions related to lung cancer WK Evans, M Wolfson, WM Flanagan, J Oderkirk,
Delete and replace with your type of Cancer. Name(s) here Period here You may edit this PowerPoint in any way you wish except for the order and titles.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Patient is a man, 60 years, smoker (60 p/y), who has lost one of his friend two week ago because of progressive lung cancer. He is worried about his.
Finding N.E.M.O. Marvin R. Balaan, MD, FCCP System Division Director, Division of Pulmonary and Critical Care Medicine Allegheny Health Network, Pittsburgh.
EPIB-591 Screening Jean-François Boivin 29 September
Cognitive Impairment: An Independent Predictor of Excess Mortality SACHS, CARTER, HOLTZ, ET AL. ANN INTERN MED, SEP, 2011;155: ZACHARY LAPAQUETTE.
5 Most Common Cancers. 1 in 2 men and 1 in 3 women in Australia will be diagnosed with cancer before the age of 85.
ACRIN BDMC Fall 2011 Biostatistics and Data Management Center Constantine Gatsonis, PhD Department of Biostatistics Center for Statistical Sciences Brown.
L. Currie 1 ; S. Keogan 1 ; P. Campbell 2 ; M. Gunning 3 Z. Kabir 1 ; V. Clarke 1 and L. Clancy 1 1 Research Institute for a Tobacco Free Society, 2 Health.
Lung Cancer Screening with Low Dose Computed Tomography Todd Robbins, MD Co-Director, Multidisciplinary Thoracic Oncology Program.
Slides last updated: October NSCLC is most often diagnosed at an advanced stage Many of the symptoms that do appear with more advanced disease can.
Implications of lung cancer screening in the new millenia Andrew R. Haas, MD, PhD Assistant Professor of Medicine Section of Interventional Pulmonary and.
Implications of lung cancer screening in the new millenia Andrew R. Haas, MD, PhD Assistant Professor of Medicine Section of Interventional Pulmonary and.
Reduced Lung Cancer Mortality Risk Among Breast Cancer Patients Treated With Anti- Estrogens Rapiti E et al. SABCS 2009;Abstract 35.
50 Shades of Pink From your Oxford Centric team. Mississippi: Now and Beyond.
[Insert Organization Name] Making the Case for Lung Cancer Screening.
BC Cancer Agency CARE & RESEARCH Breast Cancer Mortality After Screening Mammography in British Columbia Women Andrew J. Coldman, Ph.D. Norm Phillips,
REDUCED LUNG-CANCER MORTALITY WITH LOW-DOSE COMPUTED TOMOGRAPHIC SCREENING The National Lung Screening Trial Research Team N Engl J Med 2011;365:
Date of download: 5/28/2016 From: Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S.
CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Cancer Education Day Lung Cancer Screening Update Kirenza Francis, MD, FRCPC, DABR Windsor Radiological Associates May 13, 2016.
R2 정명화 D R Baldwin, S W Duffy, N J Wald, R Page, D M Hansell,J K Field Thorax ; April 2011,Vol 66.
Slide 1 Insert your own content.. Slide 2 Insert your own content.
Date of download: 6/25/2016 From: Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors.
Tobacco/Lung Cancer Working Group Participating Institutions: Case Western Reserve University; University of Washington; University of Iowa; University.
Cancer - What’s available from the LHO? David Hofman.
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Smoking and Lung Cancer
Making the Case for Lung Cancer Screening
DETERMINING RISK FOR ASBESTOS-RELATED MALIGNANCY: LUNG CANCER
Cancer.
From: Use of Decision Models in the Development of Evidence-Based Clinical Preventive Services Recommendations: Methods of the U.S. Preventive Services.
Figure 1. Multivariable risk modeling and minimally invasive biomarkers can aid the screening and diagnosis of lung cancer in high-risk individuals. BMI.
continued on next slide
Background & Objectives
DEBATE Proposition – the health service should not provide follow on services for life for TYA cancer sufferers.
FIG. 4. Working lifetime combined risk from fatal heart disease and lung cancer based on Hong Kong exposure to secondhand tobacco smoke and both US and.
Screening for Lung Cancer
                                                                                                                                                                                                                                                
continued on next slide
continued on next slide
Lung Cancer in Lewisham
Erratum Journal of Thoracic Oncology
Intellectual property of the EBCTCG trialists.
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
Colorectal Natural History Model
Slide 1 Insert your own content.. Slide 1 Insert your own content.
Lung Cancer Screening. The Pulmonologist’s Role in Improving Personalized Diagnosis and Treatment of NSCLC.
Slide 1 Insert your own content.. Slide 1 Insert your own content.
Slide 1 Insert your own content.. Slide 1 Insert your own content.
Trends in Subpopulations at High Risk for Lung Cancer
Components Necessary for High-Quality Lung Cancer Screening
Impedence-guided management
Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM)  C. Popadiuk, A.J. Coldman,
Volume 155, Issue 1, Pages (January 2019)
Smoothed colorectal cancer mortality rate (per 100 000 person-years) in the screening and control arm over follow-up time, and ratio of the mortality rates.
Published online Feb 7, 2019 Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling:
continued on next slide
Lung Cancer screening. The NELSON trial.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1. Forest plot of lung cancer mortality in LDCT trials.
continued on next slide
Presentation transcript:

LUNG CANCER SCREENING & SMOKING CESSATION

Acknowledgements

Objectives

Is it cost-effective?

Cost-Effectiveness Ratios

How do the CRMM results compare to other results?

How does the CRMM compare?

What does this mean for you?

How many people would be eligible?

What if the smoking cessation program was super expensive?

Conclusions

Limitations

Additional work

APPENDIX

What is the Cancer Risk Management Model (CRMM)?

Who is Leading the CRM?

Publications

Changes since the last presentation to the Network:

Number of new lung cancer cases by trial arm by year of study from Model and NLST

Lung Cancer Mortality Reduction

Insert jurisdictional cost slides

Over-diagnosis

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.